🎥@GABOUALFA (@MSKCancerCenter) highlights exciting anti-TIGIT therapies for hepatocellular carcinoma. Promising results from MORPHEUS-Liver trial with tiragolumab, atezolizumab, and bevacizumab: ➡️https://t.co/hR1dCQJTBi⬅️ #ASCO23 #Oncology #ImmunoOnc (@VJOncology)

Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in HCC @OncologyAdvance https://t.co/xit1v39BjF ❓What should we do and what can we expect for 2nd line therapy 🌍RWD suggest: 👉AtzeBev > Lenva 👉Lenva > ICI @myESMO @ILCAnews @EASLedu… https://t.co/ALX315Novm (@ArndtVogel)

Adding bevacizumab to trifluridine-tipiracil results in longer overall survival in refractory metastatic colorectal cancer https://t.co/UoVQSGo4CJ #fondazionebonadonna #oncology #CancerResearch @BianchiniGP @CarmenCriscit @mauricallari (@FondazioneBona1)

🎉 Celebrating #JCO's 40th: Read Dr. @EileenMOReilly's Flashback Foreword to the top-cited #JCO articles, Bevacizumab and FOLFOX4 for Colorectal Cancer (2008) and Bevacizumab v Placebo Plus Oxaliplatin-Based Chemotherapy in MCRC (2007) 👉 https://t.co/vSh3PLqCmv (@JCO_ASCO)

Resection for multifocal HCC? Only the exceptional case. It will be interesting to see how adjuvant atezo/bev changes practice. Of note, 90% of patients enrolled in the trial had a solitary HCC. https://t.co/C8mZkmJ5Rs. (@DenboJw)

Groundbreaking talk by @ReneeSaliby ⭐️ on circulating and intratumoral determinants to Atezo-Bev in non clear cell RCC #RMS #KCRS23 (@KarlSemaan)

BIOMARKERS IN RCC SYMPOSIUM 🩸 Circulating and Intratumor Immune Determinants of Response to Atezo/Bev in Patients with Variant Histology RCC @ReneeSaliby @DrChoueiri @BradMcG04 @SylvanBacaLab @BraunMDPhD @DanaFarber_GU (@MikeSerzanMD)

Adding bevacizumab to trifluridine-tipiracil results in longer overall survival in refractory metastatic colorectal cancer https://t.co/TlHjiCcl8v #fondazionebonadonna #oncology #CancerResearch @BianchiniGP @CarmenCriscit @mauricallari (@FondazioneBona1)

In patients with advanced solid tumors who have been heavily pretreated, combination therapy with #bevacizumab, #temsirolimus, and valproic acid was feasible, but numerous adverse events were observed, which will require careful management. @BlessieNelson https://t.co/NiH6O3osfT (@OncJournal)

Promising results with #microRNA miR-132-3p as strong predictive #biomarker in #VEGF pathway #mesothelioma #bevacizumab Bio-MAPS trial by @gzalcman @imig2023 #IMIG2023 (@IFCTlung)

New in @JAMANetworkOpen from Dr @imrtlee: Phase II nonRCT, no G4 hemorrhage or G5 AEs were reported with CCRT +bevacizumab for locally or regionally advanced #NPC. 5 and 7yr DMF interval rates were both ~80% even though 89% had stage III to IVB #hncsm. https://t.co/y1A6vWkN5e (@MSK_RadOnc)

What’s with the blind defense of big pharmaceutical companies? Our episode with @MikkaelSekeres was banned by YT because of purported anti-vax bias and all we did was criticize the handling of the breast cancer drug Avastin. The polarity, and dichotomous thinking, is childish. (@leonscafe31)

They deleted our episode with @MikkaelSekeres because they said it was anti-vax. Not only were vaccines not mentioned, we spoke about the breast cancer drug Avastin and Mikkael serving on the jury of the FDA trial related to it. (@leonscafe31)

IMBRAVE-050 #ASCO23. 👀 PRO exploratory analysis. 🔍 Atezo-Bev adj vs surveillance after high risk HCC resection ✅ RFS: NE x NE (HR=0.72;p=0.012) 👏 No deterioration in QoL, physical, social & emotional functions. 🧐 Should we wait OS benefit before using it? (@rcarvalhoonco)

1/Thrilled to share our work on “Circulating & intratumoral determinants of response to atezo+bev in pts with variant histology or sarco RCC” from #BraunLab @BraunMDPhD & @DrRanaMcKay out in @CIR_AACR W/ @TalalZarif1 @ZiadBakouny @ShahValisha @DrChoueiri & many others (@ReneeSaliby)

Amazing work by 🌟 superstar @ReneeSaliby investigating molecular determinants of response to Atezo+Bev among patients with #nccRCC , out now in @CIR_AACR Congrats to the whole team!!! @BraunMDPhD @DrRanaMcKay @DrChoueiri @ZiadBakouny @TalalZarif1 (@Chrislabaki1)

Our paper out @CIR_AACR! Led w/ @ReneeSaliby @ZiadBakouny #ValishaShah & mentorship from @BraunMDPhD @DrRanaMcKay @DrChoueiri. We explore circulating + tumoral biomarkers & identify correlatives of clinical outcomes in sarcomatoid/variant RCC on Atezo/Bev. https://t.co/r7yfYuqM3g (@TalalZarif1)

Abstract 4010: Phase Ib/II randomized evaluation of tiragolumab in combination with atezolizumab and bevacizumab in patients with hepatocellular carcinoma (MORPHEUS-liver study) by Dr. Richard S. Finn. A good example of biological background to add anti-TIGIT. #ASCO23 #LCSM (@HHorinouchi)

.@RutgersCancer’s Dr. Patrick Boland @PMBolandMD & colleagues present “Phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic #colorectal cancer (TABAsCO).” at #ASCO23 @ASCO https://t.co/nu7CioDzUe #ASCODailyNews #CRCSM @RWJBarnabas @RWJMS (@RutgersCancer)

Outstanding work by @ReneeSaliby on the atezolizumab + bevacizumab clinical trial in patients with variant RCC! Thrilled to have co-led this work with Renee, Valisha, and @TalalZarif1! @ASCO #ASCO23 @OncoAlert @IMG_Oncologists @DrChoueiri @BraunMDPhD @BradMcG04 @DanaFarber_GU… https://t.co/oecP7xkeYa (@ZiadBakouny)

Always a bit sad at MDT when our R0 resections don’t get Bevacizumab. Surgery in ovarian cancer likely a ‘stop gap’……..excellent drugs targeting the biology are where it is at. Although the benefits in trials seem less in cases of R0, they are not absent. (@drsadiejones)

Doubt OS will be + due to inevitable cross over. HCC is a unique disease... patients develop new primaries in the setting of chronic liver and immune dysfunction. Not confident 1 year of atezo/bev can change that. We need better biomarkers to select patients who truly benefit. (@anita_turk)

#ASCO23 A lot of interesting data on #Bispecifics in #solid tumors! 1. Abs2536 📚 💡 Update on PM8002 (PD-L1 & VEGF-A bispecific antibody) Phase Ib/IIa study. 🎯ORR of 15.2% across tumor types, w/ notable rates in cervical cancer (28%), renal cell carcinoma (26.9%),… https://t.co/yOK6WJuZL1 (@ADesaiMD)

Dr Goff on the Investigation of Adjuvant Atezolizumab Plus Bevacizumab in HCC https://t.co/XJ3twrh1CK via @onclive (@alfaro_kristin)

Lonsurf plus Avastin may be a “meaningful new treatment option” for patients with metastatic colorectal cancer who stopped responding to or cannot take chemo, findings from @TaberneroJosep showed. https://t.co/C0WA49fcRw (@cure_today)

A new randomized trial compares panitumumab and bevacizumab added to standard first-line chemotherapy for patients with left-sided, RAS wild-type metastatic colorectal cancer. https://t.co/OwrANFn49A @ILSONDavid #ColorectalCancer (@JWatch)

A new randomized trial compares panitumumab and bevacizumab added to standard first-line chemotherapy for patients with left-sided, RAS wild-type metastatic colorectal cancer. https://t.co/OwrANFn49A @ILSONDavid #ColorectalCancer (@JWatch)

Our most downloaded episode of 2022 was also banned by YouTube for several weeks. We spoke with @MikkaelSekeres about #BigPharma, the history of the FDA, and his participation in the hearing for the breast cancer drug Avastin. https://t.co/VHiHVCYdtE (@seize_podcast)

It would have spared me a near death experience (NSCLC 4B egfr exon 25) - 1L osi -> PD incl thrombosis - 2L IMpower150 -> CR And yet, I remain critical - only additive benefit? - financial burden - lifestyle & tox vs TKI only (@UfferPascal)

A phase 3 trial of bevacizumab added to trifluridine-tipiracil (FTD-TPI) in third-line therapy for metastatic colorectal #cancer is practice changing, writes Dr. @ILSONDavid. https://t.co/iZBwe0Nhn6 #ColorectalCancer (@JWatch)

These arguments just don't make sense. Sunitinib is marketed by Pfizer, all the other drugs approved in RCC by Merck/BMS/Exelixis. Same with sorafenib (bayer) and avastin+atezo (Roche). The fact that old SoC is off patent is worse for the newcomers, as it means price is a factor (@Ivaj960612)

Adding bevacizumab to treatment with trifluridine-tipiracil improves outcomes in patients with refractory, metastatic colorectal cancer. Study in @NEJMGroup. @mgfakih @elena_elez @G_LipositsMD @ChiaraCrem1 @CancerTherAdvsr https://t.co/SFn0fWWY3x (@Gastro_Advisor)

Update of ORIENT-31 trial of sintilimab (PD1) in #EGFR NSCLC @LancetRespirMed. Adding sintilimab to chemo improved PFS (HR 0.72) over chemo alone but not as much as triplet of sintilimab + IBI305 (VEGF) + chemo with PFS (HR 0.51). Similar OS across arms. https://t.co/KYtK67XtqL (@StephenVLiu)

🔥Hot of the press: ALBI Analyses of Atezolizumab & Bevacizumab versus Sorafenib in #HCC @KargerPublisher https://t.co/83GKCwja1A 🔎Post Hoc of IMbrave150 phs-III 👉ALBI prognostic & longer OS with AtezoBev in ALBI 1 🧐Observe liver function in HCC @EASLedu #livertwitter… https://t.co/4SrHr5Aj1z (@ArndtVogel)

In patients with refractory metastatic #colorectalcancer, treatment with FTD–TPI plus #bevacizumab resulted in longer overall survival than FTD–TPI alone https://t.co/2auo0o0zyq #DataViz #visualabstract #cancer #oncotwi @OncoAlert @TaberneroJosep (@mdwrtcom)

#SUNLIGHT study trifluridine–tipiracil + bevacizumab as 3-line therapy in #mCRC #CRCSM @OncoAlert ✏️mOS: 10.8 months vs 7.5 months ✏️mPFS: 5.6 months vs 2.4 months ✏️neutropenia, nausea, anemia ✏️No treatment-related deaths ✏️Time to worsening of ECOG: 9.3 months vs 6.3 months (@clacardone)

🔥Tempest announces early results for combination of TPST-1120 with Atezo/Bev in 1st line HCC ✅TPST-1120 -> PPARα agonist 🔎phs 1b/2, 70 pts 👉ORR 30% vs 17% (lower than expected in AB arm) 🧐Promsing, are we on the way to triplet Tx in HCC? @myESMO @EASLedu #livertwitter… https://t.co/0S6Uof68sN (@ArndtVogel)

MORE is better?Panitumumab vs Bevacizumab and Survival in Patients With RAS Wild-type, Left-Sided Colorectal Cancer https://t.co/AWXP9I73Zu via @JAMA_current part of @JAMANetwork @Dr_M_Tejani @drzakoncology (@JohnRTMonsonMD)

Panitumumab vs Bevacizumab and Survival in Patients With RAS Wild-type, Left-Sided Colorectal Cancer https://t.co/YOHFdVjKSi via @JAMA_current part of @JAMANetwork (@bmassutis)

DUO-O, pase III trial evaluating durvalumab in combination with chemotherapy and bevacizumab, followed by maintenance durva, bev and olaparib improved PFS in patients with advanced ovarian cancer without tumor BRCA mutations. @BHCancerCare #ovariancancer #Immunotherapy (@johndiazmd)

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden https://t.co/cxIhSqikK1 (@AndresFCardonaZ)

Atezolizumab Plus Bevacizumab in TMB-High Non-Small Cell Lung Cancers https://t.co/7OxqYInwwJ via @JAMAOnc part of @JAMANetwork (@VivekSubbiah)